PMEG
PMEG is a nuclear DNA polymerases α, δ, and ε inhibitor that causes DNA chain termination, inhibits DNA synthesis, induces cytotoxicity in dividing cells. PMEG is an acyclic nucleotide phosphonate that forms an active phosphorylated metabolite, PMEG diphosphate, within cells. PMEG has activity against leukemia and melanoma in rodent models. PMEG has poor cell permeability; its prodrug is Rabacfosadine (GS-9219) (HY-13640). PMEG shows antiviral activity against against various DNA virus infections including murine cytomegalovirus (MCMV) and human cytomegalovirus (HCMV). PMEG can be used for the research of non-hodgkin's lymphoma[1][2].
For research use only. We do not sell to patients.
- CAS No.: 114088-58-3
- Formula: C8H12N5O5P
- Molecular Weight:289.19
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All DNA/RNA Synthesis Isoforms
More
Biological Activity
Description
IC50 & Target
|
DNA Polymerase |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Ca-Ski | EC50 |
5530 nM
Compound: PMEG
|
Antiproliferative activity against HPV-transformed human CaSki cells after 7 days by SRB assay
Antiproliferative activity against HPV-transformed human CaSki cells after 7 days by SRB assay
|
[PMID: 19398642] |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
- EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
- Research Protocol for Infectious Diseases
- Cell Cytotoxicity Assay
- Mammalian live/dead viability and cytotoxicity staining
- BrdU Incorporation Assay
- Transepithelial/transendothelial electrical resistance assay
- Cell Viability Determination by MTT Colorimetric Assay
Chemical Information
-
CAS No. 114088-58-3
-
Molecular Weight 289.19
-
Formula C8H12N5O5P
-
SMILES
O=C1N=C(NC2=C1N=CN2CCOCP(O)(O)=O)N
-
Synonyms
9-(2-Phosphonylmethoxy)ethylguanine
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Solvent & Solubility
In Vitro:
DMSO : 25 mg/mL (86.45 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.64 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.64 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References
[1]. Kim HT, et al. Antiviral activity of 9-[[(ethoxyhydroxyphosphinyl)-methoxy]methoxy] guanine against cytomegalovirus and herpes simplex virus. Antiviral Res. 1995 Nov;28(3):243-51. [Content Brief]
[2]. Vail DM, et al. Assessment of GS-9219 in a pet dog model of non-Hodgkin's lymphoma. Clin Cancer Res. 2009;15(10):3503-3510. [Content Brief]
Complete Stock Solution Preparation Table
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.4579 mL | 17.2897 mL | 34.5793 mL | 86.4484 mL |
| 5 mM | 0.6916 mL | 3.4579 mL | 6.9159 mL | 17.2897 mL | |
| 10 mM | 0.3458 mL | 1.7290 mL | 3.4579 mL | 8.6448 mL | |
| 15 mM | 0.2305 mL | 1.1526 mL | 2.3053 mL | 5.7632 mL | |
| 20 mM | 0.1729 mL | 0.8645 mL | 1.7290 mL | 4.3224 mL | |
| 25 mM | 0.1383 mL | 0.6916 mL | 1.3832 mL | 3.4579 mL | |
| 30 mM | 0.1153 mL | 0.5763 mL | 1.1526 mL | 2.8816 mL | |
| 40 mM | 0.0864 mL | 0.4322 mL | 0.8645 mL | 2.1612 mL | |
| 50 mM | 0.0692 mL | 0.3458 mL | 0.6916 mL | 1.7290 mL | |
| 60 mM | 0.0576 mL | 0.2882 mL | 0.5763 mL | 1.4408 mL | |
| 80 mM | 0.0432 mL | 0.2161 mL | 0.4322 mL | 1.0806 mL |
Keywords
- PMEG
- 114088-58-3
- 9-(2-Phosphonylmethoxy)ethylguanine
- DNA/RNA Synthesis
- CMV
- Cytomegalovirus
- lymphoid cells
- DNA synthesis
- dividing cells
- leukemia
- rodent models
- client-owned pet dogs
- cytotoxicity
- anticancer agent
- ε
- high-proliferation lymphoid malignancies
- non-hodgkin's lymphoma
- spontaneous non-Hodgkin's lymphoma
- nuclear DNA polymerases α
- δ
- DNA chain termination
- melanoma
- Inhibitor
- inhibitor
- inhibit